메타클라제팜

Metaclazepam
메타클라제팜
Metaclazepam.svg
임상자료
상명탈리스
ATC 코드
  • 없는
식별자
  • 7-147o-5-(2-클로로페닐)-2-(메톡시메틸)-1-메틸-2,3-디하이드로-1,4-벤조디아제핀
CAS 번호
펍켐 CID
켐스파이더
유니
켐벨
CompTox 대시보드 (EPA)
화학 및 물리적 데이터
공식C18H18BRCLN2O
어금질량393.71 g·190−1
3D 모델(JSmol)
  • CLC1=CC=CC=C1C2=NCC(COC)N(C)C3=C2C=C(Br)C=C3
  • InChI=1S/C18H18BrClN2O/c1-22-13(11-23-2)10-21-18(14-5-3-4-6-16(14)20)15-9-12(19)7-8-17(15)22/h3-9,13H,10-11H2,1-2H3 수표Y
  • 키:WABYCCJARSRBH-UHFFFAOYSA-N 수표Y
(iii)

메타클라제팜[1](Metaclazepam, Talis라는 브랜드명으로 판매)은 벤조디아제핀 파생상품인 의약품이다.[2][3] 디아제팜이나 브로마제팜 등 다른 벤조디아제핀에 비해 진정제나 근육 이완제 성질이 떨어지는 비교적 선택적인 항불안제다.[4] 메타클라제팜의 주 대사물인 활성 대사물 N-desmethylmetaclazepam을 가지고 있다.[5] 신진대사와 노년층 간의 대사에는 큰 차이가 없다.[6]

메타클라제팜은 브로마제팜,[7] 즉 디아제팜보다 약간 더 효과적이며,[8] 15mg의 메타클라제팜은 4mg의 브로마제팜에 상당한다.[9] 메타클라제팜은 알코올과 상호작용하여 부가적인 진정제-하이프톤 효과를 낼 수 있다.[6][10] 피로는 많은 용량에서 메타클라제팜의 일반적인 부작용이다.[11] 소량의 메타클라제팜과 그 대사물들은 인간의 모유에 들어간다.[12]

참고 항목

참조

  1. ^ US 4098786
  2. ^ Borchers F, Achtert G, Hausleiter HJ, Zeugner H (1984). "Metabolism and pharmacokinetics of metaclazepam (Talis), Part III: Determination of the chemical structure of metabolites in dogs, rabbits and men". European Journal of Drug Metabolism and Pharmacokinetics. 9 (4): 325–46. doi:10.1007/bf03189684. PMID 6532806. S2CID 12290664.
  3. ^ Althaus W, Block J, Förster A, Kühnhold M, Meister D, Wischniewski M (September 1986). "Analytical profile of metaclazepam". Arzneimittel-Forschung. 36 (9): 1302–6. PMID 3790179.
  4. ^ Buschmann G, Kühl UG, Rohte O (1985). "General pharmacology of the anxiolytic compound metaclazepam in comparison to other benzodiazepines". Arzneimittel-Forschung. 35 (11): 1643–55. PMID 2868732.
  5. ^ Gielsdorf W, Molz KH, Hausleiter HJ, Achtert G, Philipp P (1986). "Pharmacokinetic profile of metaclazepam (Talis), a new 1.4-benzodiazepine. Influence of different dosage regimens on the pharmacokinetic profile of metaclazepam and its main metabolite under steady-state conditions". European Journal of Drug Metabolism and Pharmacokinetics. 11 (3): 205–10. doi:10.1007/bf03189848. PMID 3816876. S2CID 8493668.
  6. ^ a b Molz KH, Gielsdorf W, Rasper J, Jaeger H, Hausleiter HJ, Achtert G, Philipp P (1985). "Comparison of the pharmacokinetic profile of metaclazepam in old and young volunteers". European Journal of Clinical Pharmacology. 29 (2): 247–9. doi:10.1007/bf00547431. PMID 4076323. S2CID 8017809.
  7. ^ Bilone F, Roncari R (1988). "A double-blind comparison of the anxiolytic activity of two benzodiazepines, metaclazepam and bromazepam, in anxiety neurosis". Current Medical Research and Opinion. 11 (1): 45–7. doi:10.1185/03007998809111130. PMID 2898321.
  8. ^ Laakmann G, Blaschke D, Hippius H, Schewe S (May 1989). "Double-blind study of metaclazepam versus diazepam treatment of outpatients with anxiety syndrome". Pharmacopsychiatry. 22 (3): 120–5. doi:10.1055/s-2007-1014593. PMID 2568645.
  9. ^ Marano P, Patti F, Nicoletti F (1988). "Controlled study on the anxiolytic activity of a newly-developed benzodiazepine, metaclazepam". Current Medical Research and Opinion. 11 (1): 41–4. doi:10.1185/03007998809111129. PMID 2898320.
  10. ^ Schmidt V (1983). "[Experimental studies on the interaction of alcohol and metaclazepam]". Beiträge zur Gerichtlichen Medizin. 41: 413–7. PMID 6639614.
  11. ^ Laakmann G, Blaschke D, Hippius H, Schewe S (May 1988). "Double-blind randomized trial of the benzodiazepine derivative metaclazepam as compared with placebo treatment of outpatients with anxiety syndromes". Pharmacopsychiatry. 21 (3): 136–43. doi:10.1055/s-2007-1014665. PMID 2900514.
  12. ^ Schotter A, Müller R, Günther C, Hausleiter HJ, Achtert G (November 1989). "Transfer of metaclazepam and its metabolites into breast milk". Arzneimittel-Forschung. 39 (11): 1468–70. PMID 2575907.